Priority Reviews Propel FDA To Six-Year Low In Average NME Approval Time
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA's decrease in average new molecular entity approval time in 2005 was driven by an unusual preponderance of priority review drugs